Новокаинамид-Ферейн

Новокаинамид-Ферейн Uses, Dosage, Side Effects, Food Interaction and all others data.

A derivative of procaine with less CNS action.

Новокаинамид-Ферейн is an agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Новокаинамид-Ферейн appears to be similar to that of procaine and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected.

Table Of contents

• Новокаинамид-Ферейн
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Новокаинамид-Ферейн
Availability	Prescription only
Generic	Procainamide
Procainamide Other Names	Procainamida, Procainamide, Procaïnamide, Procainamidum
Related Drugs	propranolol, amiodarone, lidocaine, verapamil, Inderal, dofetilide
Type
Formula	C13H21N3O
Weight	Average: 235.3253 Monoisotopic: 235.168462309
Protein binding	15 to 20%
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	Russia
Last Updated:	September 19, 2023 at 7:00 am

Uses

Новокаинамид-Ферейн is a medication used to treat life threatening ventricular arrhythmias.

For the treatment of life-threatening ventricular arrhythmias.

Новокаинамид-Ферейн is also used to associated treatment for these conditions: Supraventricular Arrhythmias, Ventricular Tachycardia (VT), Life-threatening ventricular arrhythmias, Pre-excited atrial fibrillation

How Новокаинамид-Ферейн works

Новокаинамид-Ферейн is sodium channel blocker. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.

Toxicity

LD₅₀=95 mg/kg (rat, IV); LD₅₀=312 mg/kg (mouse, oral); LD₅₀=103 mg/kg (mouse, IV); LD₅₀=250 mg/kg (rabbit, IV)

Food Interaction

• Avoid alcohol.
• Take with food. Food reduces irritation.

Новокаинамид-Ферейн Alcohol interaction

[Minor] Ethanol may increase the acetylation of procainamide.

Subtherapeutic plasma levels of procainamide may result in some patients.

Because the acetylated metabolite of procainamide also possesses antiarrhythmic properties, the clinical effects are unclear.

Новокаинамид-Ферейн Drug Interaction

Major: haloperidol, levofloxacinModerate: ipratropium, olanzapineUnknown: aspirin, etomidate, lorazepam, diltiazem, docusate, warfarin, rosuvastatin, glucose, phenytoin, apixaban, clonazepam, furosemide, atorvastatin, enoxaparin, clopidogrel, ketorolac

Новокаинамид-Ферейн Disease Interaction

Major: cardiovascular dysfunction, proarrhythmic effects, myelosuppression, sinus-AV node dysfunction, systemic lupus erythematosusModerate: electrolyte imbalance, anticholinergic activity, renal dysfunction

Volume of Distribution

• 2 L/kg

Elimination Route

75 to 95%

Half Life

~2.5-4.5 hours

Elimination Route

Trace amounts may be excreted in the urine as free and conjugated p-aminobenzoic acid, 30 to 60 percent as unchanged PA, and 6 to 52 percent as the NAPA derivative.

Innovators Monograph

You find simplified version here Новокаинамид-Ферейн